Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Video Lectures

View video lectures on hot topics and challenging cases presented by world experts

Alopecia y psoriasis y Psoriasis y VPH: asociación infrecuente

2017

Angela Londoño, Colombia | Irene Araya, Chile
RADLA | Bogotá, Colombia

View

Psoriasis in Special Populations & Differential Diagnostics in Psoriasis

2017

Richard Langley, Canada | André Vicente de Carvalho, Brazil
RADLA | Bogotá, Colombia

View

Conozca a los Expertos de IPC - Introducción

2017

Fernando Valenzuela, Chile
RADLA | Bogotá, Colombia

View

Clinical Challenges in Psoriasis

2017

Peter van de Kerkhof, the Netherlands | Caitriona Ryan, Ireland | Jashin J. Wu, USA
Live Webcast

View

Advances in Psoriasis

2017

Peter van de Kerkhof, the Netherlands | Claudia de la Cruz, Chile | Mark Lebwohl, USA
EADV | Geneva, Switzerland

View

Psoriasis & Atopic Dermatitis - Symposium Closing

2017

Alexa Kimball, USA
AAD | Orlando, FL, USA

View

Psoriasis & Atopic Dermatitis - Immune Pathways

2017

Emma Guttman-Yassky, USA | Frank Nestle, USA
AAD | Orlando, FL, USA

View

Individualizing Treatment in Psoriasis

2017

Alan Menter, USA | April Armstrong, USA | | Christine Bundy, UK
AAD | Orlando, FL, USA

View

Search Reviews:

Filter by Topic:


Psoriasis News

8/20/2019 10:08:00 AM
Eli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).
8/6/2019 11:36:00 AM
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
8/1/2019 7:19:00 AM
On 25 May 2019, the World Health Assembly officially adopted the eleventh revision of the International Classification of Diseases (ICD-11). The ICD-11 will come into effect on 1 January 2022.
8/1/2019 7:09:00 AM
Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab)i , for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. Please see full indications and Boxed Warning for HADLIMA™, below.
More News
This website uses cookies. Please ensure your cookies are enabled. 
OK